Skip to main content

Table 1 Baseline characteristics of 65 HIV/HCV-coinfected patients with decompensated cirrhosis categorized according to receipt of anti-HCV treatment during follow-up

From: Prognostic value of liver stiffness in HIV/HCV-Coinfected patients with decompensated cirrhosis

Baseline characteristic

Patients who received HCV treatment (n = 17)

Patients who did not receive HCV treatment (n = 48)

All patients (N = 65)

Male sex - n (%)

13 (76)

30 (62)

43 (66)

Age, years – median (IQR)

46 (42–49)

46 (43–50)

46 (43–50)

HIV acquired by IDU – n (%)

12 (70)

45 (94)

57 (88)

Nadir, cells/mm3 – median (IQR)

199 (76–292)

121 (45–225)

136 (52–242)

CD4+ cells/mm3 – median (IQR)

294 (216–482)

258 (160–423)

293 (165–424)

CDC disease category C (%)

6 (35)

16 (33)

22 (34)

cART (%)

16 (94)

40 (83)

56 (86)

HIV-RNA < 5 0 copies/mL (%)

10 (59)

37 (77)

47 (71)

HBsAg-positive – n (%)

0 (0)

5(10)

5 (8)

Alcohol intake > 50 g/day – n (%)

2 (12)

11 (23)

13 (20)

First decompensation – n (%)

 Ascites

14 (82)

40 (83)

54 (83)

 Variceal bleeding

2 (12)

3 (6)

5 (8)

 Hepatic encephalopathy

0 (0)

5 (10)

5 (8)

 Non-obstructive jaundice

1 (6)

0 (0)

1 (1)

Hepatocellular carcinoma – median (IQR)

1 (6)

2 (4)

3 (4.6)

Esophageal varices – n (%)

 Yes

5 (29)

25 (52)

30 (15)

 No

8 (47)

9 (19)

17 (2)

 Unknown

4 (23)

14 (29)

18 (28)

Child-Pugh score – median (IQR)

7 (5–9)

7 (6–8)

7 (5–8)

MELD score – median (IQR)

11 (7.5–15.5)

11 (7–14)

11 (7–14)

Serum albumin, g/dL – median (IQR)

3.5 (2.4–4.2)

3.0 (2.5–3.7)

3.1 (2.5–3.9)

FIB-4 value – median (IQR)

6.5 (3.1–13.5)

6.4 (4.2–10.6)

6.4 (3.8–10.6)

Liver stiffness, kPa – median (IQR)

50 (34–70)

48 (35–63)

48 (35–64)

LSPS – median (IQR)

8.8 (4.9–17.4)

10.5 (8–16.3)

10.3 (7.6–16.4)

HCV genotype – median (IQR)

 1

12 (70)

26 (54)

38 (58)

 2

0 (0)

1 (2)

1 (1.5)

 3

3 (18)

9 (19)

12 (18.5)

 4

2 (12)

3 (6)

5 (7.7)

 Unknown

0 (0)

9 (19)

9 (13.8)

  1. Abbreviations: HCV hepatitis C virus, IQR interquartile range, HIV human immunodeficiency virus, CDC Centers for Disease Control and Prevention, cART combination antiretroviral therapy, HBsAg hepatitis B surface antigen, LSPS Liver stiffness x spleen diameter-to-platelet ratio